/VNTA

VNTA Stock - Ventana Biotech, Inc.

Q: What is the analyst price target for VNTA?

Analyst price target information is not currently available for VNTA.

Q: What is VNTA's market cap?

Market capitalization information is not currently available for VNTA.

Financial Services|Shell Companies|OTC

$0.06+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.07

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VNTA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2021

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-3.53

52W High$0.12

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2021	FY2019	FY2018
Revenue	$41,362	$31,845	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	0.0%	0.0%	N/A	N/A	N/A
Operating Income	$20,795	$18,465	$-6,975	$-300	$-600
Net Income	$19,890	$17,283	$-81,535	$-5,224	$-3,856
Net Margin	48.1%	54.3%	N/A	N/A	N/A
EPS	$0.00	$0.00	$-0.00	$-0.00	$-0.00

Company Overview

Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.

Visit Website

Frequently Asked Questions about VNTA

What is VNTA's current stock price?

Ventana Biotech, Inc. (VNTA) is currently trading at $0.06 per share. The stock has moved +0.00% today.

What is the analyst price target for VNTA?

No analyst price targets are currently available for this stock.

What sector is Ventana Biotech, Inc. in?

Ventana Biotech, Inc. operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the OTC exchange.

What is VNTA's market cap?

Ventana Biotech, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does VNTA pay dividends?

No, Ventana Biotech, Inc. does not currently pay a dividend to shareholders.